These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 8512376)

  • 21. Epoetin alfa--focus on dialyzability. Case study of the anemic patient.
    Keen ML
    ANNA J; 1995 Dec; 22(6):610-3. PubMed ID: 8633909
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Case study of the anemic patient: epoetin alfa--focus on erythrokinetics.
    Chmielewski CM
    ANNA J; 1995 Aug; 22(4):420-3. PubMed ID: 7654091
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of the therapeutic effects of epoetin zeta to epoetin alfa in the maintenance phase of renal anaemia treatment.
    Wizemann V; Rutkowski B; Baldamus C; Scigalla P; Koytchev R;
    Curr Med Res Opin; 2008 Mar; 24(3):625-37. PubMed ID: 18208642
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nursing care of predialysis patients receiving epoetin alfa.
    Brown JM
    ANNA J; 1991 Jun; 18(3):306-14. PubMed ID: 2064456
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Investigation of the efficacy of a biogeneric recombinant human erythropoietin alfa in the management of renal anemia in patients on hemodialysis: a multi-center clinical trial.
    Beiraghdar F; Panahi Y; Einollahi B; Nemati E; Ghadiani MH; Sahebkar A; Maghsoudi N; Marzony ET
    Clin Lab; 2012; 58(7-8):737-45. PubMed ID: 22997974
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Practical guidelines for the use of NESP in treating renal anaemia.
    Aljama P; Bommer J; Canaud B; Carrera F; Eckardt KU; Hörl WH; Krediet RT; Locatelli F; Macdougall IC; Wikström B;
    Nephrol Dial Transplant; 2001; 16 Suppl 3():22-8. PubMed ID: 11402087
    [No Abstract]   [Full Text] [Related]  

  • 27. Case management of the anemic patient. Epoetin alfa: focus on inflammation and infection.
    Schardin KE
    ANNA J; 1990 Dec; 17(6):468-9. PubMed ID: 2256731
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anemia and erythropoietin in hemodialysis and continuous ambulatory peritoneal dialysis.
    Korbet SM
    Kidney Int Suppl; 1993 Feb; 40():S111-9. PubMed ID: 8445832
    [No Abstract]   [Full Text] [Related]  

  • 29. Effect of facility-level hemoglobin concentration on dialysis patient risk of transfusion.
    Collins AJ; Monda KL; Molony JT; Li S; Gilbertson DT; Bradbury BD
    Am J Kidney Dis; 2014 Jun; 63(6):997-1006. PubMed ID: 24315770
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Case management of the anemic patient. Epoetin alfa: focus on kinetic dosing.
    Keen ML
    ANNA J; 1990 Aug; 17(4):318-9. PubMed ID: 2396859
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Case management of the anemic patient: epoetin alfa--focus on osteitis fibrosa.
    Morley CT
    ANNA J; 1993 Oct; 20(5):604-7. PubMed ID: 8285805
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dialysis and nutrition practices in Korean hemodialysis centers.
    Han H; Bleyer AJ; Houser RF; Jacques PF; Dwyer JT
    J Ren Nutr; 2002 Jan; 12(1):42-8. PubMed ID: 11823993
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Australian haemodialysis patients on intravenous epoetin alfa or intravenous darbepoetin alfa: how do they compare?
    Pussell BA; Walker R;
    Nephrology (Carlton); 2007 Apr; 12(2):126-9. PubMed ID: 17371333
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and tolerability of intravenous continuous erythropoietin receptor activator: a 19-week, phase II, multicenter, randomized, open-label, dose-finding study with a 12-month extension phase in patients with chronic renal disease.
    Besarab A; Salifu MO; Lunde NM; Bansal V; Fishbane S; Dougherty FC; Beyer U;
    Clin Ther; 2007 Apr; 29(4):626-39. PubMed ID: 17617286
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin.
    Besarab A; Bolton WK; Browne JK; Egrie JC; Nissenson AR; Okamoto DM; Schwab SJ; Goodkin DA
    N Engl J Med; 1998 Aug; 339(9):584-90. PubMed ID: 9718377
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Case management of the anemic patient. Focus on blood pressure and rHuEPO therapy.
    Holechek MJ; Watson AJ
    ANNA J; 1990 Feb; 17(1):72-3. PubMed ID: 2317107
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Case management of the anemic patient: epoetin alfa--focus on cognitive function.
    Corea AL
    ANNA J; 1993 Jun; 20(3):350-3. PubMed ID: 8352632
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Epoetin alfa--focus on the rehabilitation of dialysis patients. Case study of the anemic patient.
    Martin-Lester M
    ANNA J; 1996 Dec; 23(6):630-3. PubMed ID: 9069794
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Epoetin alfa--focus on patients who are hospitalized. Case study of the anemic patient.
    Chambers JK
    ANNA J; 1996 Oct; 23(5):508-11. PubMed ID: 9069780
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Switching epoetin alfa and epoetin zeta in patients with renal anemia on dialysis: Posthoc analysis.
    Więcek A; Ahmed I; Scigalla P; Koytchev R
    Adv Ther; 2010 Dec; 27(12):941-52. PubMed ID: 20972656
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.